A 79-year-old patient has received extraordinary access to an experimental obesity drug, thanks to Eli Lilly and the FDA's compassionate use program.
This drug remains in the experimental stages, raising questions about the ethics of providing such access to individuals.
The situation underscores the complex intersection of medical ethics and the availability of innovative treatments for patients in need.